anti-PD1 PLGA-PEG nanoparticles

Anti-PD1 PLGA-PEG nanoparticles represent a nano-formulated drug delivery system designed to optimize the therapeutic profile of Programmed Cell Death Protein 1 (PD-1) checkpoint inhibitors. This platform typically involves the encapsulation or surface conjugation of an anti-PD1 monoclonal antibody (such as pembrolizumab or nivolumab) within nanoparticles composed of the biodegradable copolymer poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG). The PEG component provides a hydrophilic 'stealth' layer that extends systemic circulation by reducing immune recognition and clearance, while the PLGA core facilitates the controlled, sustained release of the antibody. This formulation is primarily investigated in preclinical oncology research to enhance the local concentration of checkpoint inhibitors within the tumor microenvironment, potentially improving T-cell activation against malignant cells while minimizing the systemic immune-related adverse events (irAEs) associated with conventional antibody therapy.

Other names

anti-PD-1 PLGA-PEG NPanti-PD1 PLGA-PEG NPanti-PD 1 PLGA-PEG NPPD-1 antibody-loaded PLGA-PEG nanoparticlesPD1 antibody-loaded PLGA-PEG nanoparticlesPD 1 antibody-loaded PLGA-PEG nanoparticlesanti-PD1-encapsulated PLGA-PEG nanoparticlesanti-PD-1-encapsulated PLGA-PEG nanoparticlesanti-PD 1-encapsulated PLGA-PEG nanoparticles